Correction on St. Jude Medical’s Riata lead
This article was originally published in The Gray Sheet
Executive Summary
While concerns about the firm's Riata defibrillator lead causing perforations have been raised in journal articles and FDA adverse event reports, the firm has never issued a physician notification or alert for the device, as was erroneously reported by "The Gray Sheet" (1Oct. 13, 2008, p. 15). At a Heart Rhythm Society meeting in May, St. Jude presented an analysis from four prospective studies showing very low lead-related complication rates. The firm continues to emphasize the safety and reliability of the device
You may also be interested in...
Remote Monitoring Databases Should Also Track Pacing Leads, Experts Say
Cardiac rhythm management device manufacturers say they will register cardiac leads separately in ICD and pacemaker remote monitoring databases to better track post-market lead performance
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.